McKesson ideaShare 2025: Pharmacy of the Year Finalist Keri Bates Reflects on Teamwork, Community, and the Road Ahead

Keri Bates, PharmD, shares how the nomination validates years of hard work, highlights the deep relationships built with the community,…

Pharmacists Push Forward: Innovative Clinical Solutions Highlighted at McKesson ideaShare 2025

Pharmacy-based clinical services demonstrate both public health impact and financial sustainability.

APhA Foundation Drives Innovative Clinical Models at McKesson ideaShare 2025

Innovative pharmacist-led care models—from tech-enabled Afib screenings and HPV immunizations to Medicare-supported diabetes prevention—demonstrate how pharmacies are redefining their role…

Daily CBD Use at Consumer-Level Doses May Elevate Liver Enzymes, FDA-Led Trial Shows

CBD use can elevate liver enzymes in 5% to 6% of adults, highlighting the need for monitoring and safe usage…

McKesson ideaShare 2025: Pharmacy Technicians Drive Efficiency and Care

Empowering pharmacy technicians enhances team efficiency, improves patient care, and fosters a positive work culture, driving pharmacy success in a…

Dalpiciclib Plus Endocrine Therapy Prolonged Invasive Disease-Free Survival in HR+/HER2– Breast Cancer

Dalpiciclib combined with endocrine therapy significantly enhances progression-free survival in HR+/HER2– breast cancer, as shown in the DAWNA-A trial.

Board-Certified Psychiatric Pharmacists Have a Significant Role, Experts Say

These health care professionals are crucial to optimizing safety in medication therapy, addressing policy barriers, and the collaboration with others…

Discussing the Role of the Pharmacist in the Management of Biliary Tract Cancer

Panelists discuss how pharmacists play a crucial role in biliary tract cancer management by leveraging their detailed medication knowledge to…

Key Data and Practice Considerations for Agents Targeting HER2

Panelists discuss how trastuzumab deruxtecan demonstrated a 22% overall response rate in patients with biliary tract cancer (56.3% in HER2…